Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods,
together with associated computational tools and the growing availability of public data …

The Omicron variant of SARS-CoV-2 recently swept the globe and showed high level of
immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA …

Most SARS‐CoV‐2 proteins are translated from subgenomic RNAs (sgRNAs). While the
majority of these sgRNAs are monocistronic, some viral mRNAs encode more than one …

SARS-CoV-2 rapidly evolves during the pandemic 1 with many variants of concern (VoCs)
lineages (Supplementary Fig. S1a). Omicron (B. 1.1. 529) and its sub-lineages led to …

Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic
against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future …

Viruses are major pathogens responsible for a wide range of infectious diseases that may
lead to global pandemics. The understanding of structural underpinnings of virions …

Accumulating evidence indicates that antibodies can protect against some intracellular
pathogens. Mycobacterium bovis is an intracellular bacterium, and its cell wall (CW) is …

Background To stop the spread of the COVID-19 disease, it is crucial to create molecular
tools to investigate and diagnose COVID-19. Current efforts focus on develo** specific …

As a clinical vaccine, lipid nanoparticle (LNP) mRNA has demonstrated potent and broad
antibody responses, leading to speculation about its potential for antibody discovery. Here …